Czech RSV shot study: will parents protect their babies?
NCT ID NCT07634692
First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 5 times
Summary
This study will observe how many eligible infants in Czechia receive nirsevimab, a monoclonal antibody that helps prevent RSV, during their first RSV season. Researchers will survey parents of about 250 infants born between April 2025 and March 2027 to understand immunization rates and reasons for or against the shot. No treatment is given—this is purely an observational study to gather real-world data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi s.r.o.
Prague, 160 00, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RSV vaccine may shield babies born to mothers with HIV
- Queensland study reveals why parents say yes or no to RSV shot for babies
- New RSV vaccine for infants shows promise in major trial
- Can the RSV vaccine protect the most vulnerable? new study aims to find out
- Double defense against RSV: could Mom's vaccine plus Baby's shot be the key?
- One-dose antibody slashes RSV hospitalizations in infants